US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an antibody conjugate drug (ADC) developer operating out of the United States and China, for AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC.
Drug Profile and Development
AVZO-1418/DB-1418 is an EGFR/HER3 dual-targeting ADC based on a topoisomerase-1 inhibitor. It was developed using DualityBio’s proprietary Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform. In preclinical studies, the drug has shown higher binding affinity to tumor cells and demonstrated efficacy potential across various solid tumors, including those that are EGFR-resistant, EGFR-low, or HER3-resistant.
Financial Terms of the Agreement
Under the terms of the agreement, Avenzo will develop, manufacture, and commercialize AVZO-1418/DB-1418 globally (excluding Greater China). DualityBio will receive USD 50 million upfront and is eligible for up to approximately USD 1.15 billion in development, regulatory, and commercial milestone payments, along with tiered royalties on sales in Avenzo’s territory.
Significance of the Partnership
This licensing agreement underscores the commitment of both Avenzo Therapeutics and Duality Biologics to advancing innovative cancer therapies. By combining their expertise, the companies aim to accelerate the development and commercialization of AVZO-1418/DB-1418, potentially offering new treatment options for patients with various types of solid tumors.-Fineline Info & Tech
